Advantage Alpha Capital Partners’s Veracyte VCYT Stock Holding History

Advantage Alpha Capital Partners’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,859	Closed	-$544K	–	117
2025 Q3	$544K	Sell	15,859 -3,264	-17%	-$93.6K	0.16%	104
2025 Q2	$517K	Sell	19,123 -7,161	-27%	-$207K	0.14%	97
2025 Q1	$779K	Buy	26,284 +9,155	+53%	+$349K	0.19%	91
2024 Q4	$678K	Sell	17,129 -7,937	-32%	-$301K	0.16%	95
2024 Q3	$853K	Sell	25,066 -20,663	-45%	-$581K	0.19%	94
2024 Q2	$991K	Sell	45,729 -4,805	-10%	-$101K	0.22%	86
2024 Q1	$1.12M	Buy	50,534 +4,409	+10%	+$108K	0.21%	95
2023 Q4	$1.27M	Buy	+46,125	New	+$1.11M	0.24%	94

Other funds holding VCYT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Advantage Alpha Capital Partners's VCYT Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Veracyte (VCYT) in Q4 2025, closing a stake of 15,859 shares — an estimated $544K sold.

Advantage Alpha Capital Partners first reported a position in VCYT in Q4 2023 and held it in 8 quarters. The position peaked at $1.27M in Q4 2023. 329 funds tracked by Wall St. Rank hold VCYT as of Q4 2025.

Advantage Alpha Capital Partners reported no remaining Veracyte position as of Q4 2025 after selling out during the quarter.
Advantage Alpha Capital Partners sold 15,859 Veracyte shares in Q4 2025, an estimated $544K.
Advantage Alpha Capital Partners first reported a position in Veracyte in Q4 2023 and held it in 8 quarters.
Advantage Alpha Capital Partners's Veracyte position peaked at $1.27M in Q4 2023.
329 funds tracked by Wall St. Rank held Veracyte as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.